jshdn,
"Aug. 7, 2020
NanoLogix Sub 1-Hour Covid-19 Detection Test Further Developments
NanoLogix Begins Collaborative Efforts With Diagnostic Company and an Independent Laboratory
NanoLogix announces it has begun working with two entities to refine and further develop its patent-pending Rapid Viral Assay for COVID19 and other viruses. One is a West Coast diagnostic company and the other a long-established independent Houston laboratory.
The overall intent of this work is to obtain results to enable a detailed submission of those results to the US FDA for the purpose of receiving an Emergency Use Authorization, enabling use of the technology as a Point of Care (POC) rapid test. Secondary benefits should be publication of the resulting data in the form of at least two peer-reviewed science/medical journal papers. Grant applications are anticipated by at least one of the partners to the work. The projections for the timeline for the work range from one+ month for the independent laboratory to more than three months for the diagnostic company.
I don't know if the timeline estimated was close to being right, but this release above is about 4 months ago.
There was another release below that talked about a platform with our stuff. Also, talk of researching requirements for EUA...that was back Oct 14
"Oct. 14, 2020
NanoLogix Is Researching FDA EUA Requirements For COVID-19 Testing Related to Recently Allowed Patent
1st For Whole Virus Detection, 2nd For Antibody Detection
NanoLogix Welcomes David R. Barnhizer as Vice President For Strategic Analysis and Development
NanoLogix is researching FDA requirements for EUA's for two of the 25 covered claims in the recently allowed patent application focused upon Rapid Virus Detection. Now that there has been allowance for issue of the patent with all 25 claims allowed, NanoLogix can justify devoting resources to this process and specifics.
Upon successful results for work currently being performed by a third party to apply NanoLogix technology to a separate testing platform for COVID19 detection, other applications may follow. Once the patent is issued we will reveal the broad and detailed extent of allowed claims for this technology.
